Skip to content

Biotech Stocks

1 Buy, 2 Sells From One Of The Hottest Sectors

As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering… 

New Biotech Stocks To Watch – And More!

A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these… 

Missed Out On This Biotech’s 3,600% Surge? Further Gains May Be On The Horizon

The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the… 

This Speculative Biotech’s Treatment Candidate For Head And Neck Cancer Gives It Massive Upside Potential

With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company… 

7 ‘A-Rated’ And Aggressive Biotech Stocks To Nibble On

“These companies are all making important strides in next-gen solutions for COVID-19, cancer and other sectors. But remember, they’re small companies in a risky space, nibble on them and be patient,” advise the authors of today’s article in regards to the seven “A-rated” aggressive biotech stocks they highlight. For these seven biotech stocks – and whether they could be “Master… 

How Biotech Investors Can Survive – Or Even Take Advantage Of – This Election Season

While the author of today’s article acknowledges that “biotech investors…tend not to be a squeamish bunch”, he observes that the “looming presidential election could still cause them some visceral discomfort.” Recalling the 2016 presidential campaign, in which both major candidates’ rhetoric regarding drug pricing caused biotech stocks to plummet, he advises that “investors shouldn’t dismiss the possibility of another election-related… 

Which Of These Small-Cap Biotechs With Unique COVID-19 Vaccine Candidates Is The Better Buy?

At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.

Presidential Elections And Buying The Biotech Dip

What’s behind biotech’s recent underperformance? One important factor may be the impending presidential election – and as one exchange-traded fund strategist cited in today’s article explains, “…if history repeats, this pullback may represent an attractive buying opportunity.” What does the history of biotech’s performance leading up to and following presidential elections suggest about buying the biotech dip? CLICK HERE.

Do These Heavily Shorted Coronavirus Vaccine Stocks Present Profit Opportunities?

“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers…